DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Zydus Lifesciences Limited — Outcome of Board Meeting

NSE 2 hrs ago·11 Aug 2026, 7:54 am

Zydus Lifesciences

Zydus Lifesciences has informed stock exchanges that its board has approved the financial results for the period ending June 30, 2026. This announcement marks the formal submission of the company's performance data for the recent quarter to the market regulators.

For investors, this update is a key milestone for tracking the company's quarterly progress. It provides an opportunity to evaluate the firm's operational health and financial trajectory ahead of its official disclosure to the public.

Investors should watch for the detailed earnings report to understand the drivers behind the numbers, including revenue growth and operational efficiency, which will be crucial for assessing the company's future performance.